Cedrik M. Britten
Chief Tech/Sci/R&D Officer at IMMATICS N.V.
Net worth: 2 M $ as of 29/04/2024
Cedrik M. Britten active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMATICS N.V. | Chief Tech/Sci/R&D Officer | 31/05/2020 | - |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 31/05/2020 | - |
Career history of Cedrik M. Britten
Former positions of Cedrik M. Britten
| Companies | Position | Start | End |
|---|---|---|---|
| GSK PLC | Corporate Officer/Principal | 31/01/2015 | 30/04/2020 |
BioNTech RNA Pharmaceuticals GmbH
 BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The company is based in Mainz, Germany. | Chief Tech/Sci/R&D Officer | 31/05/2010 | 31/12/2014 |
Training of Cedrik M. Britten
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
Statistics
International
| Germany | 5 |
| United Kingdom | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| GSK PLC | Health Technology |
| IMMATICS N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The company is based in Mainz, Germany. | Health Technology |
- Stock Market
- Insiders
- Cedrik M. Britten
- Experience
